Previous Article | Next Article 
Journal of Virology, July 2001, p. 6645-6659, Vol. 75, No. 14
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.14.6645-6659.2001
Biologic Studies of Chimeras of Highly and Moderately
Virulent Molecular Clones of Simian Immunodeficiency Virus
SIVsmPBj Suggest a Critical Role for Envelope in Acute AIDS
Virus Pathogenesis
Malcolm
Haddrick,
Charles R.
Brown,
Ronald
Plishka,
Alicia
Buckler-White,
Vanessa M.
Hirsch,* and
Harold
Ginsberg
Laboratory of Molecular Microbiology,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Rockville, Maryland 20852
Received 16 February 2001/Accepted 20 April 2001
 |
ABSTRACT |
Previous studies identified three molecular clones of the acutely
pathogenic SIVsmPBj strain that varied in terms of relative in vivo
pathogenicity. One clone, SIVsmPBj6.6, reproducibly induced a rapidly
fatal disease in pigtailed macaques. In contrast, a highly related
clone (SIVsmPBj6.9) was only minimally pathogenic in macaques. PBj6.6
and PBj6.9 shared a tyrosine substitution at position 17 in the Nef
protein that is a major determinant of virulence but differed at one
residue in Vpx (C89R), three residues within the envelope (D119G,
R871G, G872R), and a single residue in Nef (F252L). SIVsmPBj6.9 was
less efficient in inducing proliferation of resting macaque peripheral
blood mononuclear cells in vitro than SIVsmPBj6.6 and exhibited a
marked reduction in infectivity relative to SIVsmPBj6.6. Chimeric
viruses for each of these variable residues were constructed, and their
biologic properties were compared to those of the parental strains.
Differences in Vpx and Nef did not alter the basic biologic phenotype
of the chimeras. However, the D119G substitution in the envelope of
SIVsmPBj6.9 was associated with a marked reduction in the infectivity
of this virus relative to SIVsmPBj6.6. An associated processing defect in gp160 of SIVsmPBj6.9 and chimeras expressing the D119G substitution suggests that a reduction in virion envelope incorporation is the
mechanistic basis for reduced virion infectivity. In vivo studies
revealed that substitution of the PBj6.9 amino acid into PBj6.6 (D119)
abrogated the pathogenicity of this previously pathogenic virus.
Introduction of the PBj6.9 G119, however, did not confer full virulence
to the parental PBj6.9 virus, implicating one or all of the other four
substitutions in the virulence of SIVsmPBj6.6.
 |
INTRODUCTION |
The infection of macaque monkeys
with simian immunodeficiency virus (SIV) is a useful animal model to
investigate the pathogenesis of human immunodeficiency virus type 1 (HIV-1). SIV-induced disease is similar to human AIDS, with the
development of high virus loads, progressive depletion of
CD4+ T cells, opportunistic infections, and death of
infected animals within a few months to years (4). In
contrast to the majority of SIV isolates, a virus isolated from a
pigtailed macaque (PBj) infected with the AIDS-inducing SIVsmm9 strain
evolved a variant pathogenesis (5, 12-15). This virus,
designated SIVsmPBj14 (for the macaque of origin and the month post-SIV
inoculation), induced an acute and lethal illness within 14 days of
inoculation characterized by profuse diarrhea, dehydration, severe
lymphopenia, and an extensive cutaneous rash. Pathologic features
included major gastrointestinal cytopathology with villus blunting
(15), massive mononuclear cell infiltration within the
gastrointestinal tract, high levels of virus replication in the
gastrointestinal-associated lymphoid tissue, and immune system
hyperactivation (14, 15). Elevated levels of cytokines
such as tumor necrosis factor alpha (14, 21, 39) and
interleukin-6 (2) produced within the sites of the lesions
(5) suggest that the pathogenesis of this novel disease
syndrome is cytokine mediated (22, 48). Evidence of increased apoptosis within gastrointestinal lesions and lymphoid tissues (18) also suggests that apoptotic mechanisms may
contribute to pathogenesis. The ability of PBj14 viruses to activate
and replicate in resting macaque peripheral blood mononuclear cells (PBMC) (13) is predictive of pathogenesis in vivo
(33).
Several representative molecular clones have been derived from the
original PBj14 biological clone (SIVsmPBj14-bcl2). Despite their common
origin, these various clones vary considerably in terms of in vivo
virulence. At least two (PBj6.6 and PBj4.19) fully reproduce the
virulence of the biologically cloned virus isolate. Two others induce
moderate symptoms (PBj6.9 and PBj1.9), and some do not appear to induce
acute disease (PBj6.12) (5, 6, 26, 33, 34). As with the
uncloned viruses, the ability of these viruses to induce proliferation
of resting PBMC appeared to be an accurate predictive marker for in
vivo pathogenicity. Sequence comparison between the parental SIVsmm9
and SIVsmmPBj14 viruses identified 36 amino acid changes throughout the
genome which might be responsible for the novel pathogenesis, as well as a duplication of the NF-
B site and an insertion in the V1 region
of Env (3, 5, 6). Several regions of the genome of
SIVsmPBj that may be important for pathogenesis have been identified. The principal pathogenic determinant identified is a mutation (17RQ to
17YE) that introduces an immunoreceptor tyrosine-based activation motif
in Nef (8). However, other unique features, such as
duplication of the NF-
B site in the long terminal repeats (LTR)
(3, 5, 32, 33), the U3 LTR promoter region
(7), the viral envelope (33, 34), and the
nef (8, 9, 37) and vpx genes
(20), play a minor role in pathogenesis.
Although the pathogenesis of the various molecular clones of SIVsmPBj
varies significantly, these viruses are remarkably similar in terms of
sequence identity. The highly pathogenic PBj6.6 and the less pathogenic
PBj6.9 viruses differ by only five amino acids distributed in three
genes of the 3' half of the genome (33). They differ at
one position within Vpx (C89R), three positions, within Env (D119G,
R871G, and G872R), and a single position within Nef (F252L).
Interestingly the Nef tyrosine mutation is present in both the PBj6.6
and PBj6.9 viruses. The purpose of the present study was to construct
chimeras between the highly pathogenic SIVsmPBj6.6 and the less
pathogenic SIVsmPBj6.9 in order to map the substitutions responsible
for the differences in their pathogenesis in vivo.
 |
MATERIALS AND METHODS |
Generation of chimeric PBj molecular clones.
The infectious
molecular clones PBj6.6 and PBj6.9 have been previously described
(33) and consist of the entire proviral DNA cloned into
pGEM3Zf(+). nef, vpx, and env exchange viruses, along with viruses containing point mutations, were generated by
standard techniques of restriction digestion (30).
Chimeric viruses resulting from the exchange of the nef,
vpx, and env genes between the PBj6.6 and PBj6.9
parental viruses are numbered, with the lower-numbered virus of a pair
corresponding to the PBj6.6 virus background. Similarly, the
higher-numbered virus of each pair corresponds to the PBj6.9 virus
background containing the PBj6.6 amino acid changes. For example, virus
018 was the PBj6.6 virus now containing the PBj6.9 Nef gene amino acid
changes and vice versa for virus 020 (PBj6.9 virus with PBj6.6 Nef).
Plasmid DNA isolations from Escherichia coli were performed
using Midi and Mini prep kits (Qiagen Inc., Santa Clarita, Calif.).
(i) nef exchange.
To generate chimeras
exchanging nef genes (018 and 020), a one-step gene
replacement procedure was used (24). The mutagenesis vector pALTER Ex-I (Altered Sites II in vitro mutagenesis system; Promega, Madison, Wis.) was modified by the addition of a
ClaI-SpeI-XhoI linker into the
NotI- and NdeI-digested plasmid.
ClaI-XhoI fragments containing the nef
gene from PBj6.6 and PBj6.9 proviral DNA were inserted into the
modified pALTER Ex-1 vector, producing pMH97.09 and -97.11, respectively. PCR products corresponding to the PBj6.6 and PBj6.9
nef genes were obtained using primers MHA6 (5'-ATG GGT
GGC GTT ACC TCC AAG AAG-3' [nucleotides 9061 to 9084]) and MHA7
(5'-TTA GCT TGT TTT CTT CTT GTC AGC C-3' [nucleotides 9846 to 9822]). Vent DNA polymerase (New England Biolabs, Inc.) was used
for the amplification with the reaction buffer supplied [10 mM KCl, 20 mM Tris-HCl (pH 8.8), 10 mM
(NH4)2SO4, 0.1% Triton X-100],
2.5 mM (each) deoxynucleoside triphosphates (Pharmacia), 25 µM (each)
primers, 1 ng of plasmid DNA template, and 1 U of enzyme activity.
Reactions were performed in a DNA thermal cycler (Perkin-Elmer) for 15 cycles (94°C for 1 min, 60°C for 1 min, 72°C for 1 min, followed
by a 5-min extension at 72°C). The gel-purified PBj6.6 nef
PCR product (1.25 pmol) was annealed to 0.05 pmol of the denatured
pMH97.11 plasmid, along with 0.25 pmol of an oligonucleotide, ampr, (Promega) that restored ampicillin resistance to the
vector, allowing for selection of the mutated constructs. DNA synthesis was achieved using T4 DNA polymerase and DNA ligase as recommended (Promega). Following transformations into ES1301 mutS E. coli and JM109 E. coli cells, nef gene
exchanges were identified by selection of colonies on Luria-Bertani
agar plates containing 125 µg of ampicillin per ml and were confirmed
by sequencing. The ClaI-XhoI fragment containing
the exchanged nef gene was built back into the parental
ClaI-XhoI-digested molecular clones.
(ii) vpx exchange.
To construct viruses 034 and
035, pGEM3Zf(+) was first digested with SmaI and
HindIII to remove the BamHI to
SphI sites from the multiple cloning site. The
HindIII end was filled with Klenow DNA polymerase, and
the blunted vector, pGEM3Zf(+) BS, was religated. EcoRI
fragments from PBj6.6 and PBj6.9 molecular clones were inserted into
the EcoRI-digested pGEM3Zf(+) BS vector. Digestion of this construct with NsiI and XbaI releases a fragment
encoding the single amino acid change that distinguishes Vpx of the
PBj6.6 virus from that of the PBj6.9 virus. The vpx exchange
was made by cloning the NsiI-XbaI fragment from
the PBj6.6 virus into the PBj6.9
NsiI-XbaI-digested EcoRI subclone and
vice versa. After confirmation by sequencing, the EcoRI
fragment containing the vpx exchange into
EcoRI-digested PBj6.6 and -6.9 DNA was inserted into the
remainder of the clone. The correct orientation of this insert was
determined by restriction digestion with the ClaI and SpeI enzymes.
(iii) gp120 exchange.
The EcoRI clones of PBj6.6
and PBj6.9 in pGEM3Zf(+) BS (described above) were digested with
XbaI and NcoI. This fragment encodes the single
amino acid change in gp120 that distinguishes PBj6.6 from PBj6.9.
Cloning the PBj6.6 XbaI-NcoI fragment into the
XbaI-NcoI-digested PBj6.9 pGEM3Zf(+) BS and vice
versa achieves the exchange. After confirmation by sequencing, the
EcoRI fragment now containing the gp120 V1 amino acid change
(position 119 of the Env protein) was built back into the PBj6.6 and
PBj6.9 parental molecular clone DNA. For both the vpx
(NsiI-XbaI) and gp120
(XbaI-NcoI) fragment exchanges between the PBj6.6
and PBj6.9 viruses, only the desired coding changes were introduced, as
the nucleotide sequences of the PBj6.6 and PBj6.9 viruses are otherwise
identical in these regions.
(iv) Viruses 120, 127, and 137.
Mutagenesis of aspartate 119 in the V1 region of the PBj envelope to arginine (R119), producing
virus 120, and to glutamate (E119), producing virus 127, was performed.
Plasmid pMH98.132 (XbaI-NcoI fragment of the V1
env region cloned into pMH97.08, a modified form of the
pALTER mutagenesis vector) was used with the oligonucleotides MHA34
(5' CC TGT TAA ACC CCA TCT TCT TGT CTC ACT TTT ATT AC 3'
[nucleotides 6931 to 6895]) and MHA39 (5' GGT GTT CCT GTT
AAA CCC CAT CTC TCT GTC TCA CTT TTA TTA CAC CTC 3' [nucleotides
6937 to 6890]) to generate viruses 120 and 127, respectively.
Mutagenesis of the third glycosylation site, g3, in the PBj envelope
was achieved by changing asparagine 153 to glutamine (N153Q) using
oligonucleotide MHA43 (5'-AAT TTT TAT ACA AGG ATC ACT GTC CTG TAC
AAC CTT TGC TGT TAT TGG 3' [nucleotides 7040 to 6993]),
producing virus 137. In each case the desired mutations were confirmed
by sequencing and by the mutated restriction fragments and were
reinserted into the PBj6.6 molecular clone.
Production and infectivity of chimeric PBj viruses.
Viruses
were produced by transfection of 293 cells (17) by the
calcium phosphate method (CellPhect Kit; Pharmacia, Piscataway, N.J.).
293 cells (5 × 106) were plated 24 h prior to
transfection and then transfected with 10 µg of plasmid DNA. The
cells were maintained in Eagle's minimum essential medium (Biofluids)
supplemented with 10% fetal bovine serum, penicillin (100 U/ml),
streptomycin (100 µg/ml), glutamine (2 mM), and HEPES (10 mM).
Culture supernatants collected at 48 h posttransfection were spun
for 10 min to remove cell debris, filtered through a
0.45-µm-pore-size filter unit (Millipore), aliquoted, and stored at
80°C. Viral stocks were quantitated by an SIV p27 Gag antigen
capture enzyme-linked immunosorbent assay (ELISA) (Retrotek) and by
reverse transcriptase (RT) activity (35). The 50% tissue
culture infective dose (TCID50) per milliliter for each
virus stock was determined on CEM 174 cells or phytohemagglutinin (PHA)-activated macaque PBMC as described previously (29,
35). To analyze the single-cycle replication of the various PBj
viruses, the MAGI-CCR5 assay was performed (45), with
minor modifications. The infection of 3 × 104 MAGI-CCR5
cells was performed with infection medium containing 16 µg of
DEAE-dextran/ml. The number of infection centers was determined by the
average of three replicate wells.
Pigtailed macaque PBMC were isolated from heparinized blood on
lymphocyte separation medium (ICN Biomedicals Inc., Aurora, Ohio)
according to the manufacturer's instructions. PBMC were activated by
the addition of PHA (Sigma, St. Louis, Mo.) to a final concentration of
0.5 µg/ml and incubated for 72 h at 37°C. The PBMC were
maintained in RPMI 1640 culture medium (Biofluids) supplemented with
10% fetal bovine serum, 10% interleukin-2 (Advanced Biotechnologies
Inc.), penicillin (100 U/ml), streptomycin (100 µg/ml), glutamine (2 mM), and HEPES (10 mM). Unstimulated or PHA-activated pigtailed macaque
PBMC were resuspended at 106 per ml in RPMI 1640 culture
medium. Virus normalized for the TCID50 titer was added to
the cells in a 1- to 2-ml volume, and the tubes were incubated for
2 h at 37°C, with mixing every 15 min. The cells were washed
twice to remove unattached virus and finally resuspended at a density
of 106 per ml. Cultures were maintained by the addition of
fresh medium as appropriate. Samples of culture supernatant were
removed at various time points to quantitate virus production by
measuring RT activity.
Proliferation assay in macaque PBMC.
Lymphocyte
proliferation was measured by the incorporation of
[6-3H]thymidine (Amersham) into the DNA of proliferating
PBMC as a consequence of activation and infection by the PBj chimeric
viruses. PBMC were isolated from blood and resuspended at
106 per ml in RPMI 1640 medium containing 10% human AB
serum (Sigma), penicillin (100 U/ml), streptomycin (100 µg/ml),
glutamine (2 mM), and HEPES (10 mM). One hundred microliters of PBMC
(105 cells) was placed into each well of a flat-bottomed
96-well microtiter Costar plate (Corning Inc., Corning, N.Y.). Virus
normalized by either p27 antigen content, RT activity, or
TCID50 was added to the PBMC in a 100-µl volume. Cultures
were incubated undisturbed for 5 days at 37°C. One microcurie of
[6-3H]thymidine (Amersham) was added to each well, and
the cultures were incubated for an additional 18 h. Cellular DNA
was isolated using a Tomtec cell harvester (Wallac, Perkin-Elmer Life
Sciences), and the tritiated thymidine incorporated was quantitated
using a 1205 Betaplate Reader scintillation counter (Wallac,
Perkin-Elmer Life Sciences). Results are expressed as a stimulation
index (SI), where the average counts per minute of five replicate wells
for each test sample was divided by the counts per minute for
uninfected PBMC (negative control).
Cell labeling and radioimmunoprecipitation.
Transfected 293 cells were labeled at 24 h posttransfection by the addition of 150 to 200 µCi of [35S]cysteine and
[35S]methionine (Amersham) in Dulbecco's modified
Eagle's minimum essential medium (DMEM) (Biofluids) lacking cysteine
and methionine. The cultures were incubated overnight at 37°C and
then lysed, and viral proteins were immunoprecipitated as described
below. For pulse-chase analyses, the transfected 293 cells were removed from the tissue culture flasks by scraping and were starved by incubation at 37°C for 30 min in DMEM lacking both cysteine and methionine. Five hundred microcuries of [35S]-labeled
cysteine and methionine was added, and the cells were incubated for an
additional 30 min at 37°C. Finally, the labeled cultures were washed
once and resuspended in complete medium and then incubated for various
time points at 37°C.
Immunoprecipitation of radiolabeled proteins was performed either on
cellular or viral lysates in 1× radioimmunoprecipitation
assay
(RIPA) buffer (20 mM Tris-HCl [pH 7.5], 5 mM EDTA, 30 mM
NaCl, 12 mM
sodium deoxycholate, and 2% NP-40). Cell lysates were
precleared by
the addition of 50 µl of protein A-agarose beads
(Gibco BRL) and 80 µl of a 1% bovine serum albumin solution (in
phosphate-buffered
saline [PBS]) by incubation at 4°C for 60 min
with agitation. The
precleared lysate was obtained by centrifugation
of the samples in a
microcentrifuge. Polyclonal serum from an
SIVsm-infected pigtailed
macaque or a macaque monoclonal antibody
specific for SIV gp120
(immunoglobulin G [IgG] 201; see reference
16) was
attached to 50 µl of protein A-agarose beads by incubation
in PBS for
60 min at 4°C. After one wash with PBS, the agarose-antibody
beads
were incubated with 0.5 to 1 ml of cell or viral lysate
at 4°C for 1 to 2 h with agitation. The cellular samples were
then washed five
times in 1× RIPA buffer, and the viral lysates
were washed three
times. The immunoprecipitated proteins were
prepared for sodium dodecyl
sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis by the
addition of an equal volume of 2× Laemmli
loading dye. The samples
were boiled for 4 min, rapidly placed
into ice, centrifuged in a
microcentrifuge for 2 min, and loaded
onto the gel. After
electrophoresis, the 10% polyacrylamide gels
were fixed by immersion
in a 30% methanol-10% acetic acid solution
for 2 h, washed
briefly in water, and enhanced by a 25-min incubation
in ENLIGHTNING
solution (NEN Life Science Products). The gels
were dried under a
vacuum at 60°C for 2 to 3 h, and protein bands
were visualized
by
autoradiography.
Spontaneous shedding of gp120 from virions.
293 cells
transfected with the PBj molecular clones were labeled at 24 h
posttransfection with 200 Ci of [35S]cysteine and
[35S]methionine overnight. The culture supernatant was
removed and filtered through a 0.45-µm-pore-size filter unit
(Millipore) and then centrifuged at 160,000 × g for 50 min at 4°C using a Beckman TL55S rotor. The resulting virus pellet
was resuspended in 1 ml of fresh Eagle's minimum essential medium.
Half of this sample was repelleted immediately, and the virus pellet
and supernatant fractions were immunoprecipitated. The other half of
the sample was incubated for 48 h at 37°C and centrifuged, and
the pellet and supernatant fractions were similarly analyzed. The
release of gp120 spontaneously shed into the supernatant from the
virion was quantitated as the percentage of the total gp120 present at that time point [(free gp120)/(gp120 on the virion) + free
gp120].
Animal studies.
Four groups of three juvenile pigtailed
macaques (Macaca nemestrina) were inoculated intravenously
with 2.15 × 103 TCID50 of PBj6.6, PBj6.9,
or the gp120 exchange viruses PBj060 and PBj063 per ml. The animals
were monitored closely for the clinical signs of PBj-induced disease.
Monkeys were maintained in accordance with the guidelines of the Animal
Care and Use Committee of the National Institutes of Health and the
Guide for the Care and Use of Laboratory Animals. Sequential
plasma samples were assayed for p27 antigenemia (p27 antigen ELISA;
Retrotek), and viral RNA levels (25) and lymphocyte
subsets were assessed daily by flow cytometric analysis (Fast Systems,
Rockville, Md.). Lymph node biopsies were obtained at day 5 postinfection. Half of the lymph node was formalin fixed and embedded
in paraffin for in situ hybridization. The remaining tissue was
separated into a single-cell suspension by passage through a Costar
cell strainer (Corning Inc.). Serial 10-fold dilutions of the lymph
node mononuclear cells (LNMCs) were cocultured with uninfected CEM 174 cells to estimate the virus load in these tissues. Virus isolation was performed weekly from 7 ml of blood by cocultivation of PHA-activated PBMC with uninfected CEM 174 cells using the supernatant RT activity as
a readout for positive virus isolation. Animals were euthanatized and
necropsied if they developed signs of acute disease, such as diarrhea,
dehydration, lethargy, and anorexia. Histopathologic analyses were
performed on lymphoid tissues and the gastrointestinal tract, and
SIV-specific in situ hybridization was performed on these tissues as
previously described (19, 20). Animals that survived the
acute phase of the PBj challenge were euthanatized 3 to 4 weeks after
inoculation, and complete necropsies were performed.
 |
RESULTS |
The molecularly cloned SIVsmPBj6.6 virus has been well
characterized as a highly pathogenic virus in pigtailed macaques
(20, 33). In contrast, the SIVsmPBj6.9 virus cloned from
the same biological isolate of SIVsmPBj appears to be considerably less pathogenic (33). Both viruses replicate in activated
macaque PBMC and monocyte-derived macrophages, but they differ
significantly in the ability to induce proliferation of resting macaque
PBMC in vitro (33). The difference in virulence of these
two cloned viruses is intriguing since sequence comparison reveals only
five amino acid differences between these viruses (Fig.
1B). Interestingly, the viruses share a
tyrosine substitution at position 17 of the Nef protein which has been
implicated in the unique pathogenesis of SIVsmPBj. Three of the
substitutions involved changes in a single gene product (C89R in Vpx,
D119G in Env, and F252L in Nef), whereas two adjacent changes mapped to
the region of overlap between the coding regions of Env and Nef. To
determine the amino acid substitutions responsible for the difference
in pathogenesis between PBj6.6 and PBj6.9, chimeric viruses were
constructed as shown in Fig. 1. A total of eight chimeras were
generated that exchanged nef, vpx, the gp120 portion of
env, and the nef-gp41 substitutions. Virus stocks
of chimeric and parental strains were generated by calcium
phosphate-mediated transfection of 293 cells and were normalized for
viral input by SIV p27 antigen content as well as TCID50
for subsequent studies of their in vitro properties.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Schematic of the SIVsmPBj virus genome showing the
genomic organization. (B) The 3' half of the PBj genome and locations
of the five amino acid differences that distinguish PBj6.6 and PBj6.9
viruses, along with the locations of the restriction sites used to make
the amino acid exchanges. (C) Schematic representation of the chimeric
and point-mutated PBj viruses. PBj6.6 virus is represented by a white
box, and PBj6.9 is represented by a black box. The nef, vpx,
and gp120 exchange viruses are numbered and shown schematically,
reflecting the exchange of amino acids between the two parental
clones.
|
|
Increased infectivity of SIVsmPBj6.6 relative to
SIVsmPBj6.9.
Each of the virus stocks was characterized for
RT activity, SIV p27 antigen content, infectivity in MAJI-CCR5 cells,
and TCID50 in CEM 174 cells. As shown in Table
1, PBj6.6 produced an average of sixfold
more SIV-expressing cells in a single cycle of infection in the
MAGI-CCR5 cell line (45) than were observed for a similar RT input of the less pathogenic PBj6.9 virus. Addionally, the specific
infectivity of the PBj6.6 and PBj6.9 virus preparations was determined
by calculating the infectivity to particle ratio (TCID50/p27 ratio) of each virus. Interestingly, we
observed that the ratio between the infectivity of the virus and viral
antigen content differed significantly between PBj6.6 and PBj6.9.
Specifically, the infectivity of the highly pathogenic PBj6.6 was
approximately 10-fold higher than that measured for PBj6.9 (19.2 versus
1.9).
The effect of different exchanges upon the infectivity of each of the
chimeric viruses was also measured. For the majority
of the chimeras,
the parental backbone of the virus (PBj6.6 or
PBj6.9) appeared to
confer the same relative difference in infectivity
between chimeric
pairs. Therefore, if the majority of the virus
consisted of PBj6.9, the
chimera had reduced infectivity relative
to the reciprocal PBj6.6
chimera. All of the viruses with the
D119G gp120 substitution proved to
be exceptions to this rule.
The specific infectivity for virus 060 (PBj6.6 virus with PBj6.9
gp120) was reduced to PBj6.9 levels
(TCID
50/p27 ratio of 1.4),
and for virus 063 (PBj6.9 virus
with PBj6.6 gp120) the ratio was
increased to 16.6. The difference in
this ratio between reciprocal
gene exchanges was unaffected by the
exchange of the
nef or
vpx genes (data not
shown). These data suggest that the D119G substitution
in the PBj6.9
envelope is responsible for reducing the specific
infectivity of this
virus relative to the virulent PBj6.6.
Proliferation of PBMC in vitro.
The ability of SIVsmPBj
viruses to induce activation and proliferation of resting PBMC in vitro
has previously been used as an indicator of pathogenesis in vivo
(33, 40). The ability of the parental viruses and the
chimeric viruses to induce proliferation of resting PBMC was assessed
by thymidine incorporation following 5 days of incubation with virus
that had been normalized for viral input by either viral antigen (10 ng
of SIV p27) or TCID50. Both methods for normalizing virus
input were used, since the specific infectivity of the virus stocks
differed widely, as described above. Using a constant input of
infectious virus, the SIs for the parental viruses and eight chimeras
were indistinguishable (data not shown).
However, using antigen levels of input virus for normalization resulted
in significant differences among the parental strains
and the chimeras,
as shown graphically in Fig.
2. As
previously
reported (
33), the PBj6.6 virus was clearly
more effective in
inducing PBMC proliferation than PBj6.9. This
differential between
the SI profiles of reciprocal chimeras remained
constant with
the
nef chimeras (018 and 020) and the
vpx chimeras (034 and 035).
In both cases, greater
proliferation was observed with the viruses
having the SIVsmPBj6.6
background. However, there was a marked
change in the profile observed
for the chimeras exchanging the
gp120 region (060 and 063). The SI for
virus 060 (PBj6.6 virus
containing PBj6.9 gp120) was considerably lower
than that for
the wild-type PBj6.6 virus (Fig.
2). Accordingly, the SI
for virus
063 (PBj6.9 virus containing PBj6.6 gp120) now showed an
increase
compared to the SI typical for the PBj6.9 virus. An analysis
of
double exchange viruses 077 (PBj6.6 virus with PBj6.9 gp120 and
PBj6.9
nef) and 088 (PBj6.9 virus with PBj6.6 gp120 and
PBj6.6
nef) further suggested that the change in PBMC
proliferation profile
was dependent on the gp120 exchange only. This
result suggested
that the extent of PBMC proliferation was determined
by the substitutions
at position 119 in the envelope gene of these
viruses.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Proliferation profile of macaque PBMC following
infection with the PBj viruses and the indicated chimeras. SIs for each
of the viruses above background levels obtained with medium alone are
shown in a bar graph format, with standard deviations indicated. PBMC
were mixed with medium alone (m), 10 ng of each virus, or PHA. The
cultures were incubated at 37°C for 5 days, and on day 6 the uptake
of 1 µCi of tritiated thymidine into the proliferating cells was
determined for five replicate wells by cell harvesting.
|
|
Kinetics of infection in activated and resting PBMC.
To
identify differences in infectivity, as suggested from the relative
abilities of PBj6.6 and PBj6.9 viruses to induce PBMC proliferation,
the growth kinetics of each virus were examined in unstimulated or
PHA-stimulated pigtailed macaque PBMC. All viruses replicated
equivalently in PHA-stimulated PBMC (data not shown). All of the
viruses also replicated in unstimulated PBMC; however, the replication
of PBj6.6 was more rapid and peak virus production was higher than for
PBj6.9 (Fig. 3). Both of the envelope exchange viruses replicated at an intermediate level when compared to
the PBj6.6 and PBj6.9 viruses. The replication of virus 060 (PBj6.6
virus containing PBj6.9 gp120) was reduced compared to wild-type PBj6.6
virus. Correspondingly, the replication of virus 063 (PBj6.9 virus
containing PBj6.6 gp120) was enhanced compared to the parental PBj6.9
virus. As the viral replication analysis was performed on unstimulated
PBMC, the resultant profiles are representations of the ability of the
viruses to both replicate in and induce the proliferation of PBMC. This
analysis indicated that for the replication of the PBj6.6 and PBj6.9
viruses in PBMC in vitro, the identity of the amino acid present at
position 119 of the gp120 protein was an important factor in
determining the growth kinetics of each virus.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Replication kinetics of the PBj viruses and the chimeras
in unstimulated macaque PBMC. Production of supernatant RT activity
following infection of unstimulated macaque PBMC with PBj6.6, PBj6.9,
060, and 063 viruses is plotted sequentially. A total of 1,200 TCID50 of each virus was used to infect 0.5 × 106 unstimulated macaque PBMC. The culture supernatant was
sampled every two days, and the RT activity was determined for the
PBj6.6 virus.
|
|
The D119G substitution is associated with a processing defect in
Env.
Since the aspartate (D119) in the V1 region of the PBj
envelope protein appeared to be involved in PBMC proliferation, viral replication, and infectivity, we evaluated its effect on gp160 processing and the interaction between gp120 and gp41. 293 cells transfected with various molecular clones were labeled with 100 to 150 µCi of [35S]methionine and [35S]cysteine,
and viral proteins were radioimmunoprecipitated from cell and viral
lysates. Immunoprecipitated proteins were resolved by gel
electrophoresis to visualize gp160 and gp120 envelope proteins associated with the cells, gp120 incorporated into virion particles, and the non-virion-associated, or free, gp120.
A comparison of the gp160 processing pattern for PBj6.6 and PBj6.9
viruses (Fig.
4, lanes 1 to 4)
demonstrated a difference
in the ratio between gp120 and gp160 protein
in cell lysates.
gp160 processing of PBj6.6 virus appeared to be
efficient, as
evidenced by the presence of significant amounts of
gp120. In
contrast, significantly less gp120 than gp160 protein was
observed
in cell lysates of the PBj6.9-producing cells. This suggested
that there is a defect in gp160 processing of PBj6.9 or a reduced
ability of the PBj6.9 gp120 protein to remain associated with
its gp41
protein at the plasma membrane. The pattern of gp160
processing of the
chimeric virus that expressed the PBj6.9-specific
glycine at position
119 in Env (lanes 5 and 6) was similar to
that of the PBj6.9 virus
(lanes 3 and 4). Correspondingly, replacement
of the glycine with
aspartate at amino acid 119 in PBj6.6 (063)
produced a processing
pattern more like that of PBj6.6 than the
parental PBj6.9 (compare
lanes 7 and 8 with lanes 1 and 2). Therefore,
the identity of the amino
acid at position 119 of the envelope
protein appeared to determine the
pattern of gp160 processing
for each virus. Viruses with
nef
exchanges had unaltered gp160
processing profiles. Thus, virus 018 (PBj6.6 with PBj6.9
nef)
showed similar processing to that
of the PBj6.6 virus. In a like
manner, virus 020 (PBj6.9 virus with
PBj6.6
nef) showed a gp160
processing efficiency similar to
that of the parental PBj6.9.
The
env gene of SIV overlaps
the
nef reading frame; therefore,
exchanging the entire
nef gene also exchanged the codons for amino
acids 871 and
872 of the envelope for each virus. This exchange
had not affected the
gp160 processing profile, further suggesting
that it was the character
of the amino acid at position 119 of
the gp120 protein that influenced
envelope polyprotein processing.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 4.
gp160 env precursor processing in 293 cells
transfected with the PBj molecular clones. 35S-labeled cell
lysates were obtained at 48 h posttransfection and analyzed by
RIPA with a polyclonal serum (PCS; odd lanes) or Fab 201 IgG to SIVsm
env (even lanes) (16). Electrophoresis was
performed on a 10% polyacrylamide-SDS gel. Lanes 1 and 2, PBj6.6;
lanes 3 and 4, PBj6.9; lanes 5 and 6, virus 060; lanes 7 and 8, virus
063; lanes 9 and 10, virus 018; lanes 11 and 12, virus 020. The
locations of gp160 and gp120 are indicated, along with the molecular
mass standards (M/kD) shown (Rainbow Markers; Promega).
|
|
Pulse-chase analysis of gp160 polyprotein processing.
To
examine the kinetics of gp160 processing, pulse-chase analysis was
performed on 293 cells at 48 h posttransfection with the various
PBj molecular clones. The transfected cells were pulse-labeled for 30 min with 500 µCi of 35S-labeled methionine and cysteine
and chased by the addition of complete medium for various time periods.
Samples were obtained every 2 h to analyze the viral envelope
proteins associated with the cellular material, and the relative
amounts of free gp120 in the culture supernatant are shown in Fig.
5.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 5.
Pulse-chase analysis of gp160 processing for 293 cells
transfected with the PBj and gp120 exchange viruses. Samples were
obtained at 0, 2, 4, 6, and 8 h and analyzed by RIPA. (A)
cell-associated gp160 processing. SIVsm Fab 201 IgG was used to
precipitate the viral envelope proteins. Lanes 1 to 5, PBj6.6 virus;
lanes 6 to 10, PBj6.9 virus; lanes 11 to 15, virus 060; lanes 16 to 20, virus 063. (B) Immunoprecipitation using a polyclonal serum of the free
gp120 in the supernatant at each time point of the pulse-chase
analysis. Lanes 1 to 5, PBj6.6 virus; lanes 6 to 10, PBj6.9 virus;
lanes 11 to 15, virus 060; lanes 16 to 20, virus 063. The locations of
the gp160 and gp120 proteins are indicated, along with the Rainbow
markers (M/kD) (Promega).
|
|
The processing of gp160 by PBj6.6 in transfected cells was efficient,
leading to significant quantities of gp120 within 2
h (Fig.
5A,
lanes 1 and 2). The relative amount of gp160 decreased
at later time
points as it was processed to gp120 protein (lanes
3 to 5). In
comparison, although PBj6.9 gp120 was also observed
by 2 h, the
relative amount of gp160 remained higher than the
amount of gp120,
suggestive of a reduction in gp160 processing.
These gp160 processing
patterns were reproduced in the envelope
exchange viruses. For virus
060 (PBj6.6 virus containing PBj6.9
gp120) a processing pattern like
that of the PBj6.9 virus was
observed (lanes 11 to 15 compared to lanes
6 to 10). Conversely,
for virus 063 (PBj6.9 virus containing PBj6.6
gp120), the gp160
processing resembled that of the PBj6.6 virus (lanes
16 to 20
compared to lanes 1 to 5), as gp120 protein remained
detectable
in the cell lysate. Thus, it appeared that the single amino
acid
change of aspartate to glycine (in virus 060) was sufficient to
produce gp160 processing that resembled that of the PBj6.9 virus.
Correspondingly, when the G119 residue was restored to D119 for
virus
063, a PBj6.6 gp160 processing pattern
resulted.
The release of free, non-virion-associated gp120 into the culture
supernatant was also examined at each time point of the
pulse-chase
assay (Fig.
5B). Supernatant samples were first centrifuged
to remove
the virions by pelleting, and then a RIPA was performed
on the
supernatant fraction. The amount of free gp120 shed from
the cells (and
virions) over the 8-h chase period is shown in
Fig.
5B. There was an
increase in the amount of free gp120 released
into the supernatant with
time for PBj6.9 virus-producing cells
compared to that observed for
cells producing PBj6.6 virus (Fig.
5B, lanes 6 to 10 compared with
lanes 1 to 5). This relative level
of free gp120 was dependent on the
amino acid present at position
119 of the gp120 protein. For virus 060 (glycine replacing aspartate)
there was an increased amount of free
gp120 compared to the gp120
present for virus 063 (aspartate replacing
glycine) over the 8
h examined (Fig.
5B, compare lanes 11 to 15 with lanes 16 to 20).
A RIPA on the pelleted virions produced during
the time course
indicated that similar levels of virus were produced,
suggesting
that the observed results were not a reflection of varying
transfection
efficiencies. These results suggested that there was a
difference
in the noncovalent association between the gp120 and gp41
envelope
protein subunits for the PBj6.6 and PBj6.9 viruses. A glycine
at position 119 of gp120 in PBj6.9 appeared to destabilize the
interaction between the gp120 and gp41 proteins, leading to a
reduction
in the amount of gp120 remaining associated with gp41
at the plasma
membrane of the cell. Correspondingly, higher levels
of free gp120 were
detected in the supernatant from PBj6.9-producing
cells than that
observed from cells producing the PBj6.6
virus.
Decreased virion-associated gp120 and increased spontaneous
shedding of PBj6.9 gp120.
To further examine the association
between the gp120 and gp41 envelope subunit and transmembrane proteins,
spontaneous gp120 shedding from radiolabeled virions was examined. As
previously reported for HIV-1 (31, 38), radiolabeled
virions were isolated from transfected culture supernatants by
centrifugation, resuspended in PBS, and divided into two equal volumes.
The viruses were incubated at 37°C for 0 or 48 h and then
repelleted by centrifugation to separate free gp120 in the supernatant
from the gp120 associated with the virion (virus pellet). A RIPA was
performed on each fraction as shown in Fig.
6, analyzed by SDS-PAGE, and quantitated
by PhosphorImager analysis. The amount of free gp120 in the supernatant
was expressed as a percentage of the total gp120 (free gp120 plus
virion-associated gp120) present at that time point.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 6.
Spontaneous shedding of gp120 from the PBj parental and
gp120 exchange viruses. 35S-labeled virions were pelleted
from transfected 293 cells and resuspended in medium. This suspension
was split into two, and each half was incubated for 0 or 48 h at
37°C and then repelleted. The free gp120 released into the
supernatant (SN; even-numbered lanes) and that remaining associated
with the virion (odd-numbered lanes) were analyzed by RIPA using a
polyclonal serum. Lanes 1 to 4, PBj6.6 virions; lanes 5 to 8, PBj6.9
virions; lanes 9 to 12, 060 virions; lanes 13 to 16, 063 virions. The
percentage of free gp120 present at each time point is shown, along
with the molecular weight markers (Promega).
|
|
As shown in Fig.
6, there was an increase in spontaneous gp120 shedding
by PBj6.9 (18.4 to 36.9%) compared to that by PBj6.6
(8.1 to 29.5%).
Similar results were obtained for the gp120 exchange
viruses (Fig.
6,
lanes 9 to 16). For virus 060 (PBj6.6 virus with
PBj6.9 gp120) the
amount of free gp120 at time zero and 48 h later
was now more
similar to that for PBj6.9 virus than for PBj6.6,
a direct result of
replacing aspartate 119 with glycine. Correspondingly,
virus 063 (PBj6.9 virus with PBj6.6 gp120) now demonstrated a
pattern virtually
identical to that of wild-type PBj6.6 virus.
Interestingly, for both
the PBj6.9 and 060 viruses (G119) there
was an increased amount of free
gp120 present at time zero when
compared to that for the PBj6.6 and 063 viruses. These results
demonstrated that the identity of the amino acid
at position 119
of gp120 was important for determining the stability of
the gp120-gp41
association on the virion envelope, with the PBj6.9
virus being
more likely to spontaneously shed gp120 than PBj6.6.
The relative amounts of gp120 present on PBj6.6 and -6.9 virions
purified through a sucrose gradient, rather than pelleted
culture
supernatant, was also estimated. Radiolabeled virions
were centrifuged
through a 20 to 60% sucrose gradient, fractionated,
and resolved by
PAGE. To determine the relative amount of gp120
on the purified
virions, the gp120 band was quantitated by phosphorimager
analysis as a
percentage of the amount of p27 protein present
in the peak fractions
from the gradient. This percentage was 2.4%
for PBj6.6 and 1.3% for
PBj6.9 virions (data not shown). This
result is consistent with earlier
observations and suggests an
approximately twofold reduction in the
amount of gp120 protein
on PBj6.9 compared to that on PBj6.6
virions.
Consistent with previous studies of soluble CD4 (sCD4)-induced shedding
of gp120 for SIV (
36), there was no increase in
gp120
shedding induced by incubation of PBj6.6 or PBj6.9 virions
with
increasing concentrations of sCD4 protein (data not shown).
Therefore,
the relative affinity for CD4 binding of the PBj6.6
and PBj6.9
envelopes as they were present on the virion could
not be directly
determined.
Mutagenesis of aspartate 119 in the PBj gp120 protein.
Sequence analysis of viral quasispecies during the development of the
SIVsmmPBj14 virus (43) revealed that the aspartate residue
at position 119 of Env arose concurrently with the development of
pathogenicity. To further characterize the role of residue 119 within
the gp120 protein, D119 of the PBj6.6 virus was changed to arginine to
give rise to virus 120 (R119) and to glutamate to give virus 127 (E119). The effect of these point mutations on Env polyprotein
precursor processing and the association of the gp120-gp41 interactions
in cell lysates was then evaluated as previously described (Fig.
7A).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 7.
gp160 processing and gp120-gp41 association for the
parental PBj and mutated viruses. (A) RIPA of gp160 processing in cell
lysates. Odd-numbered lanes were immunoprecipitated with a polyclonal
serum, and even-numbered lanes were immunoprecipitated with the SIVsm
Fab 201 IgG. PBj6.6 virus (lanes 1 and 2), PBj6.9 virus (lanes 3 and
4), and the point-mutated viruses 120 (D119R; lanes 5 and 6) and 127 (D119E; lanes 7 and 8) are shown. (B) RIPA for virion pellets of PBj6.6
virus, PBj6.9 virus, virus 120, and virus 127 is shown in lanes 1 to 4, respectively. (C) Free gp120 protein, a combination of that shed from
virions and from the surfaces of transfected cells, is shown (lane
designations are the same as for panel B). For both panels B and C a
polyclonal serum was used to immunoprecipitate the viral proteins. The
migration of molecular mass markers (M/kD) is also indicated
(Promega).
|
|
Comparing relative amounts of gp160 and gp120 revealed a reduction in
the amount of gp120 associated with the cellular material
for the
PBj6.9 virus (Fig.
7A, lanes 3 and 4) when compared to
the PBj6.6 virus
(lanes 1 and 2), as seen earlier. Introduction
of the positively
charged arginine at position 119 of PBj6.6 (virus
120) shifted the
distribution of gp160 and gp120 (lanes 5 and
6) to a pattern similar to
that observed for the PBj6.9 virus.
Introduction of a negatively
charged residue at this position,
E119 in virus 127 (lanes 7 and 8),
produced a pattern of gp160
processing similar to that of the PBj6.6
virus (lanes 1 and
2).
The distribution of the virion-associated and free gp120 for the
mutated viruses is shown in Fig.
7B and C, respectively.
No significant
difference was observed in the levels of gp120
incorporation into
virions of mutants 120 and 127. In contrast,
the level of free gp120
present was increased for PBj6.9 (lane
2) and virus 120 (R119) (lane
3). Consistent with earlier observations,
there was a reduced level of
free gp120 for both the PBj6.6 (lane
1) and 127 (E119; lane 4) viruses
when a negatively charged amino
acid was present in position 119 of the
gp120
protein.
The results suggested that the character of the amino acid at position
119 of gp120 was an important determinant of the gp120-gp41
association
at the cell surface. This also has consequences for
gp120 incorporation
into the virus particle and for spontaneous
shedding of gp120 from the
virion. The most likely explanation
for this behavior was structural
changes introduced into the envelope
proteins due to each amino acid.
Therefore, it is likely that
a negatively charged residue at position
119 of gp120 is important
for preserving optimum envelope structure and
function.
Differences in pathogenesis of parental PBj6.6 and PBj6.9
strains.
Three pigtailed macaques were inoculated intravenously
with 2 × 103 TCID50s of either PBj6.6,
PBj6.9, 060, or 063 virus to determine whether the defects in
env biology identified in vitro altered pathogenesis in
vivo. All the animals became infected, as evidenced by the rescue of
infectious virus from their PBMC (Table
2). As expected, animals inoculated with
PBj6.6 virus (1163, 7108, and 7109) developed diarrhea, generalized
skin rash, lethargy, and appetite loss. The clinical condition of these
animals necessitated euthanasia at 6 (1163 and 7108) and 8 (7109) days.
A high virus load in the lymph nodes was indicated following the
isolation of virus from as few as 1,000 LNMCs obtained at day 5 by a
lymph node biopsy. Consistent with this high virus titer, rapidly
increasing levels of viral RNA levels were measured in the plasma
associated with a rapid decline in the total lymphocyte count (Fig.
8 and 9).
Peak plasma viral RNA levels of 107 to 109/ml
were achieved by days 5 to 7 after inoculation. Histopathologic analysis of tissues of these animals revealed lesions characteristic of
SIVsmPBj. Marked pathologic changes observed in the intestine included
massive infiltration of mononuclear cells into the lamina propria and
gastrointestinal-associated lymphoid tissues, villus blunting, fusion,
and ulceration of the epithelial surface of the intestinal tract (Fig.
10). These changes were associated with large numbers of SIV-expressing cells detected by in situ hybridization (>100 SIV-positive cells per high-power field). A similarly large number of SIV-expressing cells was observed in the mesenteric lymph
nodes.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 8.
Plasma viremia in pigtailed macaques following infection
with parental PBj6.6, PBj6.9, and chimeras 060 and 063 is shown
graphically. Deaths of animals are indicated by crosses.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 9.
Absolute peripheral lymphocyte counts following
inoculation of pigtailed macaques with parental PBj6.6, PBj6.9, and
chimeras 060 and 063. Deaths of animals are indicated by crosses.
|
|

View larger version (131K):
[in this window]
[in a new window]
|
FIG. 10.
Pathologic lesions observed in macaques infected with
the highly pathogenic PBj6.6 virus (A and B) and the envelope chimera
063 (C and D). Representative fields of hematoxylin and eosin-stained
sections of the ileum and the same sections hybridized with an
SIV-specific digoxigenin-labeled antisense probe are shown for two
representative animals. Animal 1163 was inoculated with PBj6.6 (A and
B), whereas animal 1031 was inoculated with the 063 chimera (C and D).
Characteristic blunting and fusion of villi and infiltration of
mononuclear cells are seen in both animals. More erosive features are
evident in intestinal sections of the PBj6.6-inoculated macaque, and
the level of virus expression was higher than that observed in the
063-inoculated macaque.
|
|
In contrast, the pathogenesis of the PBj6.9 virus was attenuated in
macaques 1154, 7103, and 7122. Although these animals
became infected,
as evidenced by virus rescue from PBMC, plasma
antigenemia was markedly
reduced compared to that in animals inoculated
with PBj6.6 (Table
2).
Virus load in the lymph nodes at day 5
was lower than that for
PBj6.6-infected animals, as virus remained
undetected from a coculture
of up to 10
5 LNMCs with CEM 174 cells. Correspondingly, the
kinetics of plasma
viremia were slower than those observed in
PBj6.6-inoculated macaques.
Plasma viral RNA reached peak levels of
10
5 to 10
7/ml by day 12, by which time all of
the PBj6.6-inoculated macaques
had been euthanatized. Only a transient
decrease in total lymphocyte
count was observed in PBj6.9-infected
animals, and all three recovered
from the acute phase of the infection
(Fig.
8). These animals
remained free of any observable symptoms of PBj
infection and
were euthanatized at 3 weeks. No specific lesions were
observed
by histopathology. These results were similar to results
observed
in an earlier PBj6.9 animal infection study (
33),
confirming
the more attenuated pathogenesis of this
virus.
Comparison of gp120 chimeras of PBj6.6 and PBj6.9.
Inoculation
of three animals (358, 1152, and 93P027) with virus 060 (PBj6.6 virus
with PBj6.9 gp120; D119G) resulted in infection, as evidenced by the
recovery of infectious virus from PBMC (Table 2). Coculture of
104 to 105 LNMCs with CEM 174 cells allowed
recovery of virus 060 from the lymph node tissue of these animals. All
three animals survived the acute phase of infection without any
clinical symptoms and were euthanatized at the end of the experiment.
The kinetics of plasma viremia in these animals were similar to those
observed for PBj6.9-inoculated macaques, and only a transient
lymphopenia was observed (Fig. 9). Therefore, the pathogenesis of 060 appeared to be very similar to that observed with PBj6.9 virus.
Clearly, changing a single amino acid, aspartate 119 in PBj6.6 to
glycine (producing virus 060), had a dramatic effect on the
pathogenesis of infection in vivo.
Infection of animals (1031, 7100, and 93P009) with the reciprocal
chimera, virus 063 (PBj6.9 virus with PBj6.6 gp120; G119D),
led to a
consistent p27 antigenemia in two of the three animals.
Peak plasma
viral RNA levels were achieved by day 8 and ranged
from 10
6
to 10
8/ml. Tissue-associated virus load (10
4
LNMCs) was higher than for macaques inoculated with either PBj6.9
or
060 virus. The kinetics and levels of plasma viremia for one
of the
animals (1031) were indistinguishable from those observed
in
PBj6.6-inoculated macaques (Fig.
8). Animals 1031 and 7100
showed some
lymphopenia (Fig.
9), although not to the same extent
as that seen in
PBj6.6-infected animals, and were euthanatized
at days 10 and 11 due to
typical PBj symptoms. Interestingly,
animal 93P009 had a detectable
antigenemia and a similar lymphopenia
to the other 063-infected animals
but survived the acute phase
of infection and was later euthanatized at
4 weeks. Sequence analysis
of the virus isolated from this animal at
two time points did
not show any reversion of the aspartate at position
119 (data
not
shown).
The pathologic changes induced by the 063 mutant (Fig.
10A and B) were
similar to those observed for PBj6.6 but were significantly
less severe
and lacked the ulcerative features (Fig.
10C and D).
The number of
SIV-expressing cells observed in the mesenteric
lymph nodes or affected
areas of intestine was reduced at least
10-fold (5 to 20 per high-power
field) compared with representative
sections from macaques inoculated
with PBj6.6. Thus, the pathogenesis
appeared to be similar for these
two viruses, but the pathology
induced by the 063 mutant was reduced
compared to that induced
by PBj6.6. These results indicated that
replacing glycine 119
in the PBj6.9 virus with aspartate (producing
virus 063) produced
a more pathogenic virus than the PBj6.9 parental
virus. However,
virus 063 remained less pathogenic than the PBj6.6
virus, suggesting
that other amino acid substitutions may need to be
introduced
into the PBj6.9 background to completely reconstruct PBj6.6
pathogenesis.
 |
DISCUSSION |
The construction and evaluation of chimeric viruses are a
valuable approach which has provided new insights into viral
pathogenesis. In an earlier study based on SIVsmPBj6.6 and SIVsmmH4
chimera construction, env in combination with an additional
unknown gene was identified as a determinant of pathogenesis
(33). We have extended these observations by the analysis
of chimeras derived from two highly related PBj parental viruses to
more precisely identify sequence differences that specify the phenotype
of each virus. Chimeric viruses were constructed between the acutely
pathogenic PBj6.6 and less pathogenic PBj6.9 viruses. Of the five amino
acid differences that distinguish these parental viruses, the single amino acid exchange of aspartate to glycine at position 119 of gp120
(D119G) was identified as an important component of PBj pathogenesis.
The present study demonstrates the importance of the envelope
glycoprotein of primate lentiviruses such as SIV in viral pathogenesis.
A single substitution within gp120 of the SIVsmPBj6.9 molecular clone
was responsible for reducing the relative infectivity of viral
particles in vitro and completely abrogated the virulence of
SIVsmPBj6.6 in vivo. This specific mutation was clearly responsible for
the attenuated phenotype of the less pathogenic SIVsmPBj6.9 molecularly
cloned virus. However, this PBj6.6 gp120 substitution alone was not
sufficient to restore full virulence to SIVsmPBj6.9. Therefore,
SIVsmPBj6.9 must contain an additional attenuating mutation(s) relative
to SIVsmPBj6.6.
The retroviral envelope glycoprotein is an important determinant of
both viral replication and tropism. Env is synthesized as a gp160
polyprotein precursor which is glycosylated and then cleaved by a host
protease, producing the extracellular gp120 subunit and the gp41
transmembrane viral protein. These proteins remain associated together
by a noncovalent interaction and become incorporated into nascent
virions at the plasma membrane of the cell (reviewed in reference
11). Previous reports have shown that amino acid changes
within the V1-V2 region of the HIV-1 envelope glycoprotein affect both
gp160 polyprotein precursor processing and the association between the
gp120 and gp41 cleavage products (11, 28, 42). However, it
is uncertain what the effect of altered envelope processing or changes
in the affinity of the gp120-gp41 interaction may have on the
pathogenesis of the virus in vivo.
Introduction of the D119G exchange into the PBj6.6 virus led to a
reduction in virus infectivity as reflected in slower replication kinetics in MAGI-CCR5 cells and PBMC in vitro (Fig. 2 and 3 and Table
1). Correspondingly, introduction of the reciprocal G119D exchange into
the PBj6.9 virus increased the infectivity of the chimera relative to
the parental PBj6.9 virus. The stability of the gp120-gp41 interaction
was analyzed for the PBj viruses. The presence of aspartate at position
119 in the PBj6.6 and 063 viruses produced an optimal gp160 processing
pattern in cells, with the incorporation of gp120 into virions as well
as a quantity of shed, or free, gp120 (Fig. 4, 5, and 6). When glycine
replaced aspartate in viruses PBj6.9 and 060, gp160 processing was less
efficient, with a reduction in the amount of gp120 remaining associated
with the surface of the virus-producing cells and a corresponding
increase in the level of free gp120 shed from cells and virions.
The decrease in the stability of the gp120-gp41 association probably
accounts for the reduced ability of PBj6.9 and 060 viruses to infect
cells relative to that of PBj6.6 and 063 (Fig. 3 and Table 1). Reduced
infectivity due to increased shedding of gp120 has been described for
HIV-1 (31). Altered physical and functional properties of
gp120 have been shown to directly affect viral infectivity involving
subunit association (42, 44, 49). Attempts to better
characterize the affinity of the PBj gp120-gp41 interaction by
analyzing sCD4-induced shedding of PBj gp120 were unsuccessful (data
not shown), as sCD4 does not induce gp120 shedding for SIVs, unlike
HIV-1 env (36). Although sCD4 has been shown to
increase the infectivity of SIVs (1), recent studies
indicate that the mechanism may be by the sCD4-induced increase in
binding of gp120 to CCR5 rather than by exposure of the fusogenic
domain in gp41 as a result of gp120 shedding as proposed for HIV-1
(36).
Comparing the mutated viruses 120 (R119) and 127 (E119) to PBj6.6
(D119) and PBj6.9 (G119), it was clear that a negatively charged amino
acid was preferred at this position of gp120 (Fig. 7). The consequences
of replacing aspartate (PBj6.6) with the small and highly polar glycine
(PBj6.9) as well as with the oppositely charged arginine (virus 120)
would be expected to alter the structure of the local V1 region or
perhaps the entire gp120 protein. When the more conservative glutamate
substitution was made (virus 127), gp160 processing efficiency and the
gp120 distribution profile were similar to those observed for the
PBj6.6 virus, suggesting that the negative charge was essential in this
region if not the aspartate itself. However, aspartate is highly
conserved at this position for many SIV isolates (data not shown).
Similarly, it was shown for HIV-1 that a single and highly conserved
aspartate residue between the V1 and V2 region was critical for the
early stages of viral replication (47).
Using the SIV animal model allows the pathogenic consequences of the
defects in PBj envelope biology identified in vitro to be examined in
vivo. PBj6.6- and PBj6.9-infected animals demonstrated a predictable
and expected pathogenesis. PBj6.6 was highly pathogenic, resulting in
the death of two animals at day 6 and of the remaining animal at day 8 from the typical PBj enteric syndrome. However, those macaques that
received PBj6.9 virus had attenuated pathogenesis; all
PBj6.9-inoculated animals survived the initial acute phase of the
disease with only superficial clinical symptoms, as observed previously
(33). However, infection of animals with the
env exchange viruses produced a clear change in
pathogenesis. Animals that were infected with virus 060 (D119G)
displayed a pathogenesis that was very similar to that observed for
PBj6.9. These animals survived the initial phase of the infection and
failed to demonstrate any major clinical symptoms, even though they
were genuinely infected. The only difference between virus 060 and the
parental PBj6.6 was the D119G exchange. Therefore, the complete loss of
acute pathogenicity by introducing the D119G mutation into PBj6.6
demonstrates the importance of this amino acid and the V1 region of gp120.
In contrast, virus 063 (G119D) infection produced a more severe
pathogenesis than that observed for its PBj6.9 parent. Two of the three
animals (1031 and 7100) succumbed to virus 063 infection, at days 9 and
11 postinfection. The pathogenesis appeared similar to that seen with
PBj6.6, although it was less aggressive and somewhat delayed. The
kinetics and pattern of plasma viremia were shifted earlier than those
observed in macaques inoculated with the PBj6.9 parent. However, there
was more variability in the kinetics of viremia and lower peak levels
than were observed in PBj6.6-inoculated macaques. Furthermore, in situ
analysis of the pathologic changes observed in representative gut
tissue sections associated with viruses 063 and PBj6.6 indicated that
although the pathology was similar, there were less extensive
cytopathic effects observed for the 063-infected animals. Therefore,
virus 063 had a much more pathogenic phenotype than the PBj6.9 parental background as a direct result of introducing the single amino acid
change G119D, but chimera 063 was not as pathogenic as the PBj6.6
virus. Animal 93P009, which was also infected with virus 063, survived
the infection despite showing an initial steep decline in total
lymphocyte subsets and clinical symptoms. Sequencing analysis of the
virus recovered from animal 93P009 on two separate occasions
demonstrated that the mutation (G119D) of gp120 had been retained.
While the introduction of D119G into PBj6.6 clearly reduced the
pathogenicity of the 060 chimera, the inability to fully reconstruct
PBj6.6 pathogenesis in the PBj6.9 background by making the reciprocal
G119D exchange (virus 063) suggests that additional amino acid
exchanges are required in Nef or Vpx.
It is now well established that PBj Nef, with the essential 17YE amino
acid sequence as part of an immunoreceptor tyrosine-based activation
motif, is a major determinant of PBj pathogenesis (8, 9). Mutagenesis of SIVmac239 to SIVmac239YE resulted in a virus with typical PBj properties; however, these infected animals mostly survived the initial acute phase of the disease. Correspondingly, mutagenesis of the Nef YE sequence in the PBj6.6 virus abrogated pathogenesis (37), and disruption of this sequence was
found to occur in surviving animals following a mucosal route of
infection with SIV PBj14 (39). However, it is likely that
the YE-encoding nef mutation alone is insufficient to
specify the most severe PBj pathogenesis, because both PBj6.6 and
PBj6.9 viruses have an identical Nef YE sequence. The only sequence
difference between these two viruses is at position 252 of Nef. The
phenylalanine residue is only present in PBj6.6 (data not shown) and is
seemingly an unimportant sequence difference, as indicated by the in
vitro assays performed here. In addition, replacing the nef
3' LTR region of the nonpathogenic simian-human immunodeficiency virus
strain PPc (SHIVPPc) with the PBj14 nef LTR
region produced virus SHIVPPc PBjnef, which was able to
induce PBMC activation in vitro but failed to replicate productively in
vivo. This indicates that PBj nef alone was insufficient to
cause a pathogenic infection in vivo, indicating that an interaction
between the PBj nef and PBj env was required for
pathogenesis (41). Our results are consistent with the
involvement of PBj env and nef, i.e., the reduced
pathogenicity of virus 060 with the D119G gp120 mutation and the
enhanced pathogenicity of virus 063 as a result of the G119D mutation,
although both viruses had the same Nef 17YE sequence.
An alternative amino acid exchange that may be involved in PBj disease
is that encoded by the vpx gene. Vpx has been shown to be
required for replication in macrophages in vitro (27), and
more recently, for acute pathogenesis of SIVsmPBj in vivo (20). A vpx deletion mutant PBj virus that was
impaired for macrophage infection failed to establish a pathogenic
infection in vivo, indicating that a macrophage-dependent mechanism may be a prerequisite for vpx-dependent viral amplification.
However, previous studies have demonstrated that SIVsmPBj6.9 is capable of infecting macrophages in vitro. Therefore, if the vpx
substitution is important for modulating the acute pathogenesis of
SIVsmPBj6.9, it would not appear to be through effects on replication
in macrophages. When the vpx exchange alone was introduced
into PBj6.6 and PBj6.9 parents, generating viruses 034 and 035, respectively, no alteration in the biologic behavior relative to the
parental viruses was observed with in vitro assays. Of course, this may
be because these assays were not for vpx function per se and
instead were a readout of virus infectivity, of which the gp120
exchanges would be dominant. Therefore, it is possible that along with
the G119D mutation introduced into PBj6.9, it may also be necessary to
make the Vpx R89C exchange to compensate for any defect in
vpx function. Perhaps the reduced total number of
SIV-positive cells and the reduced cytopathicity observed by in situ
hybridization in addition to the delayed acute phase pathogenesis
observed in vivo were due to a lack of viral spread involving the
vpx gene.
In conclusion, the identification of important PBj pathogenic
determinants must attempt to identify the order of precedence and the
combinations required of the various amino acid changes needed to
completely reconstruct PBj6.6 pathogenesis in a PBj6.9 background. Our
approach has clearly indicated that the function of env is
an important component of PBj pathogenesis, where the stability of the
gp120-gp41 interaction appears to influence viral infectivity. It has
recently been shown by antiviral intervention treatment of PBj-infected
animals that viral replication is an important part of the acute phase
of the disease (23), which is consistent with our
observations. However, this study indicates that it may be the
interplay and combination of the env gene, the YE Nef
protein, and even the vpx gene that together are necessary and sufficient to specify acute or severe PBj pathogenesis. These results indicate the important consequences that single amino acid
changes, which occur frequently during replication of the viral genome
by reverse transcriptase, can contribute to virus pathogenesis.
 |
ACKNOWLEDGMENTS |
We thank Malcolm Martin for support; Eric Freed for assistance in
performing RIPAs; Simoy Goldstein, Sonya Whitted, and Robert Goeken for
technical assistance; and Russell Byrum and Marisa St. Claire for
conducting the animal studies.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Twinbrook II Facility, 12441 Parklawn Dr., Rockville, MD
20852. Phone: (301) 496-2976. Fax: (301) 480-2618. E-mail: vhirsch{at}nih.gov.
 |
REFERENCES |
| 1.
|
Allan, J. S.,
J. Strauss, and D. W. Buck.
1990.
Enhancement of SIV infection with soluble receptor molecules.
Science
247:1084-1088[Abstract/Free Full Text].
|
| 2.
|
Birx, D.,
M. G. Lewis,
M. Vahey,
K. Tencer,
P. Zack,
C. R. Brown,
P. B. Jahrling,
G. Tosato,
D. Burke, and R. Redfield.
1993.
Association of interleukin-6 in the pathogenesis of acutely fatal SIVsmmPBj14 in pigtailed macaques.
AIDS Res. Hum. Retrovir.
9:1123-1129[Medline].
|
| 3.
|
Courgnaud, V.,
F. Lauré,
P. N. Fultz,
L. Montagnier,
C. Bréchot, and P. Sonigo.
1992.
Genetic differences accounting for evolution and pathogenicity of simian immunodeficiency virus from a sooty mangabey monkey after cross-species transmission to a pig-tailed macaque.
J. Virol.
66:414-419[Abstract/Free Full Text].
|
| 4.
|
Desrosiers, R. C.
1990.
The simian immunodeficiency viruses.
Annu. Rev. Immunol.
8:557-578[CrossRef][Medline].
|
| 5.
|
Dewhurst, S.,
J. E. Embretson,
D. C. Anderson,
J. I. Mullins, and P. N. Fultz.
1990.
Sequence analysis and acute pathogenicity of molecularly cloned SIVsmm-PBj14.
Nature (London)
345:636-640[CrossRef][Medline].
|
| 6.
|
Dewhurst, S.,
J. E. Embretson,
P. N. Fultz, and J. I. Mullins.
1992.
Molecular clones from a non-acutely pathogenic derivative of SIVsmmPBj14: characterization and comparison to acutely pathogenic clones.
AIDS Res. Hum. Retrovir.
8:1179-1187[Medline].
|
| 7.
|
Dittmar, M. T.,
K. Cichutek,
P. N. Fultz, and R. Kurth.
1995.
The U3 promoter region of the acutely lethal simian immunodeficiency virus clone smmPBj1.9 confers related biological activity on the apathogenic clone agm3mc.
Proc. Natl. Acad. Sci. USA
92:1362-1366[Abstract/Free Full Text].
|
| 8.
|
Du, Z.,
S. M. Lang,
V. G. Sasseville,
A. A. Lackner,
P. O. Ilyinskii,
M. D. Daniel,
J. U. Jung, and R. C. Desrosiers.
1995.
Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys.
Cell
82:665-674[CrossRef][Medline].
|
| 9.
|
Du, Z.,
P. O. Ilyinskii,
V. G. Sasseville,
M. Newstein,
A. A. Lackner, and R. C. Desrosiers.
1996.
Requirements for lymphocyte activation by unusual strains of simian immunodeficiency virus.
J. Virol.
70:4157-4161[Abstract].
|
| 10.
|
Freed, E. O., and M. A. Martin.
1994.
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein.
J. Virol.
68:2503-2512[Abstract/Free Full Text].
|
| 11.
|
Freed, E. O., and M. A. Martin.
1995.
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection.
J. Biol. Chem.
270:23883-23886[Free Full Text].
|
| 12.
|
Fultz, P. N.,
H. M. McClure,
D. C. Anderson, and W. M. Switzer.
1989.
Identification and biologic characterization of an acutely lethal variant of simian immunodeficiency virus from sooty mangabeys (SIV/smm).
AIDS Res. Hum. Retrovir.
5:397-409[Medline].
|
| 13.
|
Fultz, P. N.
1991.
Replication of an acutely lethal simian immunodeficiency virus activates and induces proliferation of lymphocytes.
J. Virol.
65:4902-4909[Abstract/Free Full Text].
|
| 14.
|
Fultz, P. N.
1994.
SIVsmmPBj14: an atypical lentivirus.
Curr. Top. Microbiol. Immunol.
188:65-76[Medline].
|
| 15.
|
Fultz, P. N., and P. M. Zack.
1994.
Unique lentivirus-host interactions: SIVsmmPBj14 infection of macaques.
Virus Res.
32:205-225[CrossRef][Medline].
|
| 16.
|
Glamann, J.,
D. R. Burton,
P. W. H. I. Parren,
H. J. Ditzel,
K. A. Kent,
C. Arnold,
D. Montefiori, and V. M. Hirsch.
1998.
Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
J. Virol.
72:585-592[Abstract/Free Full Text].
|
| 17.
|
Graham, F. L.,
J. Smiley,
W. C. Russell, and R. Nairns.
1977.
Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
J. Gen. Virol.
36:59-74[Abstract/Free Full Text].
|
| 18.
|
Gummuluru, S.,
F. J. Novembre,
M. Lewis,
H. A. Gelbard, and S. Dewhurst.
1996.
Apoptosis correlates with immune activation in intestinal lymphoid tissue from macaques acutely infected by a highly enteropathic simian immunodeficiency virus, SIVsmmPBj14.
Virology
225:21-32[CrossRef][Medline].
|
| 19.
|
Hirsch, V. M.,
G. Dapolito,
P. R. Johnson,
W. R. Elkins,
W. T. London,
R. J. Montali,
S. Goldstein, and C. Brown.
1995.
Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication.
J. Virol.
69:955-967[Abstract].
|
| 20.
|
Hirsch, V. M.,
M. E. Sharkey,
C. R. Brown,
B. Brichacek,
S. Goldstein,
J. Wakefield,
R. Byrum,
W. R. Elkins,
B. H. Hahn,
J. D. Lifson, and M. Stevenson.
1998.
Vpx is required for dissemination and pathogenesis of SIVsmPBj: evidence of macrophage-dependent viral amplification.
Nat. Med.
4:1401-1408[CrossRef][Medline].
|
| 21.
|
Hodge, S.,
F. J. Novembre, and S. Dewhurst.
1998.
Endogenous tumor necrosis factor-alpha contributes to lymphoproliferation induced by simian immunodeficiency virus variant, SIVsmmPBj14.
Immunol. Lett.
63:49-51[CrossRef][Medline].
|
| 22.
|
Hodge, S.,
F. J. Novembre,
L. Whetter,
H. A. Gelbard, and S. Dewhurst.
1998.
Induction of fas ligand expression by an acutely lethal simian immunodeficiency virus, SIVsmmPBj14.
Virology
252:354-363[CrossRef][Medline].
|
| 23.
|
Hodge, S.,
J. de Rosayro,
A. Glenn,
I. C. Ojukwu,
S. Dewhurst,
H. M. McClure,
N. Bischofberger,
D. C. Anderson,
S. A. Klumpp, and F. J. Novembre.
1999.
Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj.
J. Virol.
73:8630-8639[Abstract/Free Full Text].
|
| 24.
|
Huang, Y.,
L. Zhang, and D. D. Ho.
1995.
Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection.
J. Virol.
69:8142-8146[Abstract].
|
| 25.
|
Igarashi, T.,
Y. Endo,
G. Englund,
R. Sadjadpour,
T. Matano,
C. Buckler,
A. Buckler-White,
R. Plishka,
T. Theodore,
R. Shibata, and M. Martin.
1999.
Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus.
Proc. Natl. Acad. Sci. USA
96:14049-14054[Abstract/Free Full Text].
|
| 26.
|
Israel, Z.,
G. A. Dean,
D. H. Maul,
S. P. O'Neill,
M. J. Dreitz,
J. I. Mullins,
P. N. Fultz, and E. A. Hoover.
1993.
Early pathogenesis of disease caused by SIVsmmPBj14 molecular clone 1.9 in macaques.
AIDS Res. Hum. Retrovir.
9:277-285[Medline].
|
| 27.
|
Kawamura, M.,
H. Sakai, and A. Adachi.
1994.
Human immunodeficiency virus vpx is required for the early phase of replication in peripheral blood mononuclear cells.
Microbiol. Immunol.
38:871-878[Medline].
|
| 28.
|
Koito, A.,
G. Harrowe,
J. A. Levy, and C. Cheng-Mayer.
1994.
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.
J. Virol.
68:2253-2259[Abstract/Free Full Text].
|
| 29.
|
Lifson, J. D.,
M. A. Nowak,
S. Goldstein,
J. L. Rossio,
A. Kinter,
G. Vasquez,
T. A. Wiltrout,
C. Brown,
D. Schneider,
L. Wahl,
A. L. Lloyd,
J. Williams,
W. R. Elkins,
A. S. Fauci, and V. M. Hirsch.
1997.
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.
J. Virol.
71:9508-9514[Abstract].
|
| 30.
|
Maniatis, T.,
E. F. Fritsch, and J. Sambrook.
1982.
Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 31.
|
McKeating, J. A.,
A. McKnight, and J. P. Moore.
1991.
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
J. Virol.
65:852-860[Abstract/Free Full Text].
|
| 32.
|
Novembre, F.,
V. M. Hirsch,
H. M. McClure, and P. R. Johnson.
1991.
Molecular diversity of SIVsmm/PBj and a cognate variant, SIVsmm/PGg.
J. Med. Primatol.
20:188-192[Medline].
|
| 33.
|
Novembre, F. J.,
P. R. Johnson,
M. G. Lewis,
D. C. Anderson,
S. Klumpp,
H. M. McClure, and V. M. Hirsch.
1993.
Multiple viral determinants contribute to pathogenicity of the acutely lethal simian immunodeficiency virus SIVsmmPBj variant.
J. Virol.
67:2466-2474[Abstract/Free Full Text].
|
| 34.
|
Novembre, F. J.,
M. M. Saucier,
V. M. Hirsch,
P. R. Johnson, and H. M. McClure.
1994.
Viral genetic determinants in SIVsmmPBj pathogenesis.
J. Med. Primatol.
23:136-145[Medline].
|
| 35.
|
Peden, K. W. C., and M. A. Martin.
1995.
In
J. Karn (ed.), HIV: a practical approach, vol. 1. , p. 23-25.
IRL Press, New York, N.Y.
|
| 36.
|
Sattentau, Q. J., and J. P. Moore.
1991.
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
J. Exp. Med.
174:407-415[Abstract/Free Full Text].
|
| 37.
|
Saucier, M.,
S. Hodge,
S. Dewhurst,
T. Gibson,
J. P. Gibson,
H. M. McClure, and F. J. Novembre.
1998.
The tyrosine-17 residue of nef in SIVsmmPBj14 is required for acute pathogenesis and contributes to replication in macrophages.
Virology
244:261-272[CrossRef][Medline].
|
| 38.
|
Schneider, M.,
O. Kaaden,
T. D. Copeland,
S. Oroszlan, and G. Hunsmann.
1986.
Shedding and interspecies type sero-reactivity of the envelope glycopeptide gp120 of the human immunodeficiency virus.
J. Gen. Virol.
67:2533-2538[Abstract/Free Full Text].
|
| 39.
|
Schwiebert, R. S.,
B. Tao, and P. N. Fultz.
1997.
Loss of the SIVsmmPBj14 phenotype and nef genotype during long-term survival of macaques infected by mucosal routes.
Virology
230:82-92[CrossRef][Medline].
|
| 40.
|
Schwiebert, R. S., and P. N. Fultz.
1994.
Immune activation and viral burden in acute disease induced by simian immunodeficiency virus SIVsmmPBj14: correlation between in vitro and in vivo events.
J. Virol.
68:5538-5547[Abstract/Free Full Text].
|
| 41.
|
Stephens, E. B.,
S. Mukherjee,
Z. Q. Liu,
D. Sheffer,
R. Lamb-Wharton,
K. Leung,
W. Zhuge,
S. V. Joag,
Z. Li,
L. Foresman,
I. Adany, and O. Narayan.
1998.
Simian-human immunodeficiency virus (SHIV) containing the nef/long terminal repeat region of the highly virulent SIVsmmPBj14 causes PBj-like activation of cultured resting peripheral blood mononuclear cells, but the chimera showed no increase in virulence.
J. Virol.
72:5207-5214[Abstract/Free Full Text].
|
| 42.
|
Sullivan, N.,
M. Thali,
C. Furman,
D. D. Ho, and J. Sodroski.
1993.
Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.
J. Virol.
67:3674-3679[Abstract/Free Full Text].
|
| 43.
|
Tao, B., and P. N. Fultz.
1995.
Molecular and biological analyses of quasispecies during evolution of a virulent simian immunodeficiency virus, SIVsmmPBj.
J. Virol.
69:2031-2037[Abstract].
|
| 44.
|
Thali, M.,
C. Furman,
E. Helseth,
H. Repke, and J. Sodroski.
1992.
Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.
J. Virol.
66:5516-5524[Abstract/Free Full Text].
|
| 45.
|
Vodicka, M. A.,
W. C. Goh,
L. I. Wu,
M. E. Rogel,
S. R. Bartz,
V. L. Schweickart,
C. J. Raport, and M. Emerman.
1997.
Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.
Virology
233:193-198[CrossRef][Medline].
|
| 46.
|
Wang, W.-K.,
M. Essex, and T.-H. Lee.
1996.
Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revert.
J. Virol.
70:607-611[Abstract].
|
| 47.
|
Wang, W.-K.,
M. Essex, and T.-H. Lee.
1995.
The highly conserved aspartic acid residue between hypervariable regions 1 and 2 of human immunodeficiency virus type 1 gp120 is important for early stages of virus replication.
J. Virol.
69:538-542[Abstract].
|
| 48.
|
Whetter, L.,
F. J. Novembre,
M. Saucier,
S. Gummuluru, and S. Dewhurst.
1998.
Costimulatory pathways in lymphocyte proliferation induced by the simian immunodeficiency virus SIVsmmPBj14.
J. Virol.
72:6155-6158[Abstract/Free Full Text].
|
| 49.
|
Willey, R. L.,
M. A. Martin, and K. W. Peden.
1994.
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.
J. Virol.
68:1029-1039[Abstract/Free Full Text].
|
Journal of Virology, July 2001, p. 6645-6659, Vol. 75, No. 14
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.14.6645-6659.2001
This article has been cited by other articles:
-
Goldstein, S., Brown, C. R., Ourmanov, I., Pandrea, I., Buckler-White, A., Erb, C., Nandi, J. S., Foster, G. J., Autissier, P., Schmitz, J. E., Hirsch, V. M.
(2006). Comparison of Simian Immunodeficiency Virus SIVagmVer Replication and CD4+ T-Cell Dynamics in Vervet and Sabaeus African Green Monkeys.. J. Virol.
80: 4868-4877
[Abstract]
[Full Text]
-
Hsu, M., Harouse, J. M., Gettie, A., Buckner, C., Blanchard, J., Cheng-Mayer, C.
(2002). Increased Mucosal Transmission but Not Enhanced Pathogenicity of the CCR5-Tropic, Simian AIDS-Inducing Simian/Human Immunodeficiency Virus SHIVSF162P3 Maps to Envelope gp120. J. Virol.
77: 989-998
[Abstract]
[Full Text]
-
Dehghani, H., Brown, C. R., Plishka, R., Buckler-White, A., Hirsch, V. M.
(2002). The ITAM in Nef Influences Acute Pathogenesis of AIDS-Inducing Simian Immunodeficiency Viruses SIVsm and SIVagm without Altering Kinetics or Extent of Viremia. J. Virol.
76: 4379-4389
[Abstract]
[Full Text]